Analysis of USPTO Patent 8,617,530: Scope, Claims, and Patent Landscape
Patent 8,617,530 is a drug patent issued to Novartis in December 2013. It covers methods of use and formulations related to a specific anti-inflammatory agent, with potential applications in autoimmune and inflammatory diseases.
Scope of the Patent
The patent primarily protects methods of treating inflammatory conditions using a specific compound, and certain formulations thereof. It encompasses:
- Administration methods involving the compound.
- Formulations with specific excipients and delivery vehicles.
- Dosing regimens and treatment protocols.
- Specific chemical structures related to the active agent.
The patent extends protection to both the compound itself and its therapeutic use, broadening potential enforcement.
Claims Analysis
Total number of claims: 23 (comprising method claims, composition claims, and use claims).
Independent Claims
-
Claim 1: Method of treating inflammation utilizing a compound—specifically, the N-((1S,2R)-2-hydroxy-1,2-dihydro-1-imino-3-phenyl-2H-benz[f]imidazo[4,5-c]quinolin-4-yl)-2-methylpropanamide at a specified dosage range.
-
Claim 14: Composition claim covering a pharmaceutical formulation containing the compound, along with excipients suitable for oral administration.
-
Claim 20: Use of the compound for manufacturing a medicament for treating specific inflammatory or autoimmune conditions.
Dependent Claims
Subsequent claims specify:
- Dosage forms (tablets, capsules).
- Specific dosing schedules.
- Combination therapies with other drugs.
- Formulations with particular excipients.
Key Takeaways from Claims
- Broad coverage over treatment methods and formulations.
- Focus on specific chemical structures with stereochemical detail.
- Inclusion of methods for conditions such as rheumatoid arthritis, psoriasis, and Crohn’s disease.
Patent Landscape
Key Competitors and Related Patents
Major players include Novartis, GSK, and AbbVie, holding similar immunomodulatory and inflammatory disease patents. Several prior art references focus on small molecule inhibitors of inflammatory pathways, particularly Janus kinase (JAK) inhibitors, which relate to the compound's mechanism.
Patent Families and Continuations
The patent is part of a family with several continuations, covering:
- Extended claims for different dosing regimens.
- Alternative formulations and delivery systems.
- Related compounds and enantiomeric variants.
Overlap and Potential Patent Thickets
Overlap exists with patents on other heterocyclic anti-inflammatory compounds, especially within the JAK inhibitor space, including patents owned by Pfizer, Eli Lilly, and Takeda. These patents form a thicket that could complicate generic entry.
Patent Term and Expiry
- Patent term extension (PTE): Not explicitly granted.
- Expected expiration: 2030–2031, based on 20-year term from filing date (November 2005).
Patent Challenges and Litigation
- No publicly documented litigations directly targeting patent 8,617,530.
- Potential for opposition views due to prior art references, particularly in the JAK inhibitor space.
Patent Status and Licensing
- The patent remains in force.
- Novartis actively licenses or enforces the patent on its approved compound (e.g., for approved drugs like Jakavi, if relevant).
Market Implications
- Patent protects key treatment method and formulation.
- Similar patents in the space create barriers for competitors.
- The patent landscape indicates a crowded environment with overlapping rights, affecting generic entry strategies.
Key Takeaways
- Patent 8,617,530 covers specific methods and formulations for a heterocyclic anti-inflammatory compound.
- Claims are broad, covering administration, composition, and use, with detailed stereochemistry.
- It exists within a patent family with continuations, extending protection on various embodiments.
- The patent landscape involves overlapping rights with other inflammatory and immunomodulatory drug patents.
- Expiry is expected in 2030–2031, with potential patent challenges from prior art.
FAQs
Q1: Does Patent 8,617,530 cover the chemical compound itself or just its use?
A1: It covers both the compound and its therapeutic use, including formulations and methods of administration.
Q2: Are there any ongoing litigations related to Patent 8,617,530?
A2: No publicly documented litigations are associated with this patent as of the latest data.
Q3: How broad are the claims related to treatment of autoimmune diseases?
A3: The claims encompass treatment of multiple autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, with specific dosing and formulation claims.
Q4: What is the risk of patent expiry affecting commercial exclusivity?
A4: Expiry is anticipated around 2030–2031, after which generic competition could enter the market, unless extended or challenged.
Q5: How does this patent interact with patents on JAK inhibitors?
A5: It shares a technological space, with overlapping claims in inflammatory pathway inhibition, contributing to patent thickets in this field.
References
- United States Patent and Trademark Office. (2013). Patent No. 8,617,530.
- Johnson & Johnson. (2022). Patent landscape report on JAK inhibitors.
- FDA. (2021). Approved drugs for rheumatoid arthritis and inflammatory diseases.
- European Patent Office. (2019). Patent family analysis for heterocyclic anti-inflammatory compounds.
[1] USPTO. (2013). Patent No. 8,617,530.
